文献速递造血干细胞移植与细胞治疗白血病MDS 与骨髓增殖性肿瘤

供者克隆性造血与移植后受者结局

Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation.
PubMed 文献 · J Clin Oncol · 2021-11-18

该研究对1727名40岁及以上供者样本进行靶向纠错测序,评估供者克隆性造血对受者临床结局的影响,并测量102个供者克隆的长期植入及256名受者移植后3和12个月细胞因子水平。结果显示供者克隆性造血与受者结局密切相关,供者DNMT3A克隆性造血与受者生存改善相关,供者细胞白血病风险由体细胞骨髓增生异常综合征相关突变或胚系易感性驱动。

要点

  • 供者克隆性造血见于22.5%的供者,以DNMT3A(14.6%)和TET2(5.2%)突变最常见。
  • 85%的供者克隆在移植后受者中显示长期植入,包括变异等位基因频率<0.01的克隆。
  • 供者DNMT3A克隆性造血(变异等位基因频率≥0.01)与受者总生存和无进展生存改善相关。

核心结论

  • 供者克隆性造血与移植受者临床结局密切相关,对移植物同种免疫功能和白血病转化潜能的影响因突变基因和体细胞克隆丰度而异。
  • 供者DNMT3A克隆性造血通过降低复发风险与受者生存改善相关,并与受者炎症细胞因子网络增强相关。
  • 异基因造血干细胞移植中供者细胞白血病的风险由供者体细胞骨髓增生异常综合征相关突变或胚系易感性驱动。

研究设计与样本

  • 对1727名40岁及以上供者的样本进行靶向纠错测序,评估供者克隆性造血对受者临床结局的影响。
  • 测量102个供者克隆的长期植入,以及256名受者移植后3和12个月的细胞因子水平。

主要发现

  • 供者克隆性造血见于22.5%的供者,DNMT3A突变占14.6%,TET2突变占5.2%。
  • 85%的供者克隆在移植后受者中显示长期植入,包括变异等位基因频率<0.01的克隆。
  • 校正显著临床变量后,变异等位基因频率≥0.01的DNMT3A克隆性造血与受者总生存改善相关(HR 0.79;P=0.042),与无进展生存改善相关(HR 0.72;P=0.003),更小的克隆无此关联。
  • 在接受以钙调神经磷酸酶抑制剂为基础的移植物抗宿主病预防的患者中,供者DNMT3A克隆性造血与复发减少相关(亚分布HR 0.59;P=0.014),与慢性移植物抗宿主病增加相关(亚分布HR 1.36;P=0.042),并与受者白细胞介素-12p70水平升高相关。
  • 无单独DNMT3A或TET2克隆性造血受者发生供者细胞白血病;8例供者细胞白血病中7例源于供者克隆性造血,携带罕见TP53或剪接因子突变,或来自携带胚系DDX41突变的供者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Clonal hematopoiesis (CH) can be transmitted from a donor to a recipient during allogeneic hematopoietic cell transplantation. Exclusion of candidate donors with CH is controversial since its impact on recipient outcomes and graft alloimmune function is uncertain. PATIENTS AND METHODS: We performed targeted error-corrected sequencing on samples from 1,727 donors age 40 years or older and assessed the effect of donor CH on recipient clinical outcomes. We measured long-term engraftment of 102 donor clones and cytokine levels in 256 recipients at 3 and 12 months after transplant. RESULTS: CH was present in 22.5% of donors, with DNMT3A (14.6%) and TET2 (5.2%) mutations being most common; 85% of donor clones showed long-term engraftment in recipients after transplantation, including clones with a variant allele fraction < 0.01. DNMT3A-CH with a variant allele fraction ≥ 0.01, but not smaller clones, was associated with improved recipient overall (hazard ratio [HR], 0.79; P = .042) and progression-free survival (HR, 0.72; P = .003) after adjustment for significant clinical variables. In patients who received calcineurin-based graft-versus-host disease prophylaxis, donor DNMT3A-CH was associated with reduced relapse (subdistribution HR, 0.59; P = .014), increased chronic graft-versus-host disease (subdistribution HR, 1.36; P = .042), and higher interleukin-12p70 levels in recipients. No recipient of sole DNMT3A or TET2-CH developed donor cell leukemia (DCL). In seven of eight cases, DCL evolved from donor CH with rare TP53 or splicing factor mutations or from donors carrying germline DDX41 mutations. CONCLUSION: Donor CH is closely associated with clinical outcomes in transplant recipients, with differential impact on graft alloimmune function and potential for leukemic transformation related to mutated gene and somatic clonal abundance. Donor DNMT3A-CH is associated with improved recipient survival because of reduced relapse risk and with an augmented network of inflammatory cytokines in recipients. Risk of DCL in allogeneic hematopoietic cell transplantation is driven by somatic myelodysplastic syndrome-associated mutations or germline predisposition in donors.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Gibson CJ, Kim HT, Zhao L, et al. Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. J Clin Oncol. 2021. PMID: 34793200. doi:10.1200/JCO.21.02286

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。